Esmolol is antiarrhythmic in doxorubicin-induced arrhythmia in cultured cardiomyocytes - determination by novel rapid cardiomyocyte assay.
Cardiac toxicity is an uncommon but potentially serious complication of cancer therapy, especially with anthracyclines. One of the most effective anticancer drugs is doxorubicin, but its value is limited by the risk of developing cardiomyopathy and ventricular arrhythmia. When applied to a network of periodically contracting cardiomyocytes in culture, doxorubicin induces rhythm disturbances. Using a novel rapid assay based on non-invasive ion-conductance microscopy we show that the beta-antagonist esmolol can restore rhythm in doxorubicin-treated cultures of cardiomyocytes. Moreover, esmolol pre-treatment can protect the culture from doxorubicin-induced arrhythmia.
Gorelik
Julia
J
MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College of Science, Technology and Medicine, London, UK.
Vodyanoy
Igor
I
Shevchuk
Andrew I
AI
Diakonov
Ivan A
IA
Lab
Max J
MJ
Korchev
Yuri E
YE
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy*; D018929:Cell Culture Techniques / Q000379:methods; D004317:Doxorubicin / Q000494:pharmacology*; D004336:Drug Antagonism; D008955:Models, Cardiovascular; D009200:Myocardial Contraction / Q000187:drug effects; D032383:Myocytes, Cardiac / Q000166:cytology / Q000187:drug effects*; D011412:Propanolamines / Q000494:pharmacology*; D051381:Rats
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D011412:Propanolamines; D004317:Doxorubicin; C036604:esmolol